In vitro, activation of PKM2 increases glucose metabolic flux by partially increasing glycolytic flux and PGC-1α mRNA in cultured podocytes, thereby inhibiting the production of toxic glucose metabolites, inducing mitochondrial production, and restoring mitochondrial functions to prevent diabetic nephropathy (DN) (57). Here, PPARGC1A is linked to liver dysplastic nodule.